by | Jan 12, 2026 | Ly, Amy, Maher, Christopher, Maher, Nicole, Nickless, Andrew, Webster, Jace, Zhang, Jin
— Published date: 1/13/2026
Value Proposition: Predictive biomarkers that can identify patients that would respond well to HER2 targeted breast cancer treatment that are not currently being treated this way.
Technology Description
Researchers at Washington University in St. Louis have establis…
by | Nov 12, 2021 | Cabanski, Christopher, Fields, Ryan, Maher, Christopher, Silva-Fisher, Jessica
— Technology Description
Researchers in Prof. Christopher Maher’s research program (in conjunction with collaborator Ryan Fields) discovered that RAMS11 (RNA Associated with Metastasis 11), a novel long non-coding RNA, (i) promotes metastatic disease, (ii) confers resistance to topoisomerase i…
by | Jun 9, 2020 | Chaudhuri, Aadel, Maher, Christopher, Pachynski, Russell
— Technology Description
A team of researchers at Washington University has developed “EnhanceAR-Seq”, a circulating tumor DNA (ctDNA) assay that predicts which patients are at high risk for developing resistance to androgen receptor (AR)-directed treatment for metastatic prostate cancer…